This Article Full Text Full Text (PDF) All Versions of this Article: 38/3/865    most recent 01.STR.0000257974.06317.49v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilcox, R. Search for Related Content PubMed PubMed Citation Articles by Wilcox, R. Related Collections Cardiovascular Pharmacology Type 2 diabetes Secondary prevention

(Stroke. 2007;38:865.)
© 2007 American Heart Association, Inc.

Original Contributions

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke

Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

Robert Wilcox, MD; Marie-Germaine Bousser, MD; D. John Betteridge, MD; Guntram Schernthaner, MD; Valdis Pirags, MD; Stuart Kupfer, MD; John Dormandy, DSc for the PROactive Investigators

From the Department of Cardiovascular Medicine (R.W.), Queen’s Medical Centre, University Hospital, Nottingham, UK; 2 Rue Ambroise Paré 75475 (M.-G.B.), Paris, France; Department of Medicine (D.J.B.), University College Hospital, London, UK; Department of Medicine I (G.S.), Rudolfstiftung Hospital, Vienna, Austria; Paula Stradina Kliniska Universitates Slimnica (V.P.), Riga, Latvia; Takeda Global Research and Development (S.K.), Deerfield, Ill; and Department of Clinical Vascular Research (J.D.), St. Georges Hospital, London, UK.

Correspondence to Prof Robert G Wilcox, Department of Cardiovascular Medicine, Queen’s Medical Centre, University Hospital, Nottingham, UK NG7 2UH. E-mail robert.wilcox{at}nottingham.ac.uk

Background and Purpose— Diabetes is an important risk factor for stroke. We conducted analyses in patients who had entered the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) with a history of stroke or without stroke.

Methods— The prospective, double-blind PROactive (mean duration, 34.5 months) randomized 5238 patients with type 2 diabetes and a history of macrovascular disease to pioglitazone (titrated to 45 mg) or placebo, in addition to current diabetes and cardiovascular medications. Cardiovascular end-point events were independently adjudicated. This analysis evaluated the risk of stroke and other cardiovascular outcomes in patients with (n=984) and without (n=4254) prior stroke.

Results— In patients with previous stroke (n=486 in the pioglitazone group and n=498 in the placebo group), there was a trend of benefit with pioglitazone for the primary end point of all-cause death, nonfatal myocardial infarction, acute coronary syndrome, and cardiac intervention (including coronary artery bypass graft or percutaneous coronary intervention), stroke, major leg amputation, or bypass surgery or leg revascularization (hazard ratio[HR]=0.78, event rate=20.2% pioglitazone vs 25.3% placebo; 95% CI=0.60–1.02; P=0.0670) and for the main secondary end point of all-cause death, nonfatal myocardial infarction, or nonfatal stroke (HR=0.78, event rate=15.6% pioglitazone vs 19.7% placebo; 95% CI=0.58–1.06; P=0.1095). Pioglitazone reduced fatal or nonfatal stroke (HR=0.53, event rate=5.6% pioglitazone vs 10.2% placebo; 95% CI=0.34–0.85; P=0.0085) and cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR=0.72, event rate=13.0% pioglitazone vs 17.7% placebo; 95% CI=0.52–1.00; P=0.0467). Higher event rates were observed in patients with prior stroke compared with those without prior stroke. In patients without prior stroke, no treatment effect was observed for a first stroke.

Conclusions— In a subgroup analysis from PROactive, pioglitazone reduced the risk of recurrent stroke significantly in high-risk patients with type 2 diabetes.

Key Words: clinical trials • pioglitazone • stroke • type 2 diabetes

This article has been cited by other articles:

				Z. T. Bloomgarden Cardiovascular Disease in Diabetes Diabetes Care, June 1, 2008; 31(6): 1260 - 1266. [Full Text] [PDF]

				D. J. Betteridge, R. A. DeFronzo, and R. J. Chilton PROactive: time for a critical appraisal Eur. Heart J., April 2, 2008; 29(8): 969 - 983. [Abstract] [Full Text] [PDF]

				Glitazones in type 2 diabetes: an update DTB, April 1, 2008; 46(4): 25 - 29. [Abstract] [Full Text] [PDF]

				D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]

				E. Erdmann and R. G. Wilcox Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur. Heart J., January 1, 2008; 29(1): 12 - 20. [Abstract] [Full Text] [PDF]

				T. Kanda, S. Wakino, K. Hayashi, and J. Plutzky Cardiovascular Disease, Chronic Kidney Disease, and Type 2 Diabetes Mellitus: Proceeding with Caution at a Dangerous Intersection J. Am. Soc. Nephrol., January 1, 2008; 19(1): 4 - 7. [Full Text] [PDF]

				T. Nakamura, E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama Pioglitazone Exerts Protective Effects Against Stroke in Stroke-Prone Spontaneously Hypertensive Rats, Independently of Blood Pressure Stroke, November 1, 2007; 38(11): 3016 - 3022. [Abstract] [Full Text] [PDF]

				L. Castilla-Guerra and M. del Carmen Fernandez-Moreno Stroke in Diabetic Patients: Is It Really a Macrovascular Complication? Stroke, October 1, 2007; 38(10): e106 - e106. [Full Text] [PDF]

				Z. T. Bloomgarden The Avandia Debate Diabetes Care, September 1, 2007; 30(9): 2401 - 2408. [Full Text] [PDF]

				Recurrent Stroke Risk Reduced With Pioglitazone DOC News, May 1, 2007; 4(5): 14 - 14. [Full Text]